We discuss management of eyes with both geographic atrophy and neovascular AMD with Dr. Ted Leng of the Byers Eye Institute, Stanford University School of Medicine

We review the 6 month results of the Davio 2 trial of the Durayvu TKI delivery system for maintenance therapy of neovascular AMD with Dr. Carl Regillo of Wills Eye Hospital.

We discuss the latest promising results from the GALE extension study of pegcetacoplan with Dr. Ashkan Abbey of Texas Retina Associates

We discuss the promising phase I results of the Helios trial studying AXPAXLI TKI inhibitor implant for diabetic retinopathy with Dr. Dilsher Dhoot of California Retina Consultants.

We discuss the use of non steroidal inflammatory agents in the management of central serous chorioretinopathy with Dr. Michael Singer of San Antonio, Texas

We discuss remarkable preliminary results from the the use of intravitreal EYE-103, a novel Wnt pathway agonist in the treatment of DME and neovascular AMD with Dr. Charles Wykoff of Houston Texas.

We discuss the first interim results of a novel intravitreal gene therapy agent, 4D-150, with Dr. Arshad Khanani of Sierra Eye Associates and the University of Nevada Reno School of Medicine.

We discuss the use of a novel bispecific anti-VEGF Anti IL-6 Antibody Biopolymar Conjugate for the treatment of DME with Dr. Mark R. Barakat of Phoenix, AZ.